Delivering Meaningful Innovation
Advancing the Treatment of PAD. We’re the only company to offer multiple drug-eluting technologies for treating PAD and received CE Mark approval for the ELUVIA™ Drug-Eluting Vascular Stent System in February 2016. In clinical trials, ELUVIA showed one of the highest patency rates ever reported for a peripheral vascular device. Restoring the Flow. The launch of the AngioJet™ ZelanteDVT™ Thrombectomy Catheter further solidifies our position as the market leader in catheter-based procedures to clear dangerous DVT blood clots. We’re investing in new technologies and education to help advance DVT treatment.
Tumor-Tackling Technologies. We broadened our Interventional Oncology portfolio with the recent acquisition of spherical embolic technologies developed by CeloNova Biosciences, Inc., including the Embozene and Oncozene microspheres. These precisely calibrated spheres are designed to prevent blood flow to the targeted tissue and slow tumor growth.
Conditions We Treat
Solutions We Offer
2. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis Fowkes, F Gerald R et al. The Lancet , Volume 382 , Issue 9901 , 1329 - 1340.
3. Alvaro Alonso, MD, and Lawrence A. Garcia. The Costs of Critical Limb Ischemia. Endovascular Today. 2011; Aug: 32-36
4. American Cancer Society. Key Statistics on Liver Cancer. http://www.cancer.org/cancer/livercancer/detailedguide/liver-cancer-what-is-key-statistics. Accessed March 23, 2016.